Nautilus Biotechnology operates as a publicly traded corporate entity whose shares are listed on the NASDAQ stock exchange under the ticker symbol NAUT. As a public company, its financial statements, insider transactions, and corporate governance filings are subject to rigorous regulatory disclosure standards. Ownership is distributed among institutional asset management firms, mutual funds, venture capital backers, and individual retail investors participating in open market trading.